CD226 and colorectal carcinoma: Although CD155 has been demonstrated to play a role in CD226 loss of expression via proteasomal degradation of CD226 [20], our results indicated no correlation between CD155 and CD226 expression in CRC with liver metastasis, suggesting the existence of other mechanisms that drive loss of CD226 expression in the TME.